---
layout: post
title: New Drug Approvals 2012 - Pt. XXVI - cabozantinib (COMETRIQTM)
date: '2013-01-06T02:54:00.002Z'
author: Bissan Al-Lazikani
tags:
- Kinase inhibitor
- Black Box Warning Drugs
- 2012 New Drugs
modified_time: '2013-01-06T03:12:02.343Z'
thumbnail: http://4.bp.blogspot.com/-iY6NjwRLseY/ULm5-u_eZyI/AAAAAAAAALI/1MBgbJorabw/s72-c/COMETRIQTM.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-513690857317190759
blogger_orig_url: http://chembl.blogspot.com/2013/01/new-drug-approvals-2012-pt-xxvi.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-iY6NjwRLseY/ULm5-u_eZyI/AAAAAAAAALI/1MBgbJorabw/s1600/COMETRIQTM.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/-iY6NjwRLseY/ULm5-u_eZyI/AAAAAAAAALI/1MBgbJorabw/s1600/COMETRIQTM.png" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<center>
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,0,0,2,0,0,0,0,1" width="400" /></center>
<center>
</center>
<center>
<b>ATC code:</b> not yet assigned</center>
<center>
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Cabozantinib">Cabozantinib</a></center>
<br />
On November 29th, the FDA approved &nbsp;Cometriq<sup>TM</sup>(cabozantinib, research code XL-184) for the treatment of patients with progressive, metastatic, medullary thyroid cancer (MTC). MTC is a rare type of thyroid cancer accounting for 5-10% of all diagnosed thyroid cancers (<a href="http://www.cancerresearchuk.org/cancer-help/type/thyroid-cancer/about/types-of-thyroid-cancer">CRUK</a>). A quarter of MTC cases are familial and are caused by a mutation in the <i>RET</i> gene. Clinical studies showed that cabozantinib increases progression-free survival time to 11.2 months in comparison with 4 months for placebo.<br />
<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-VB-kSp2B1mU/ULnH7nmx8-I/AAAAAAAAALY/lUkoRRKKM2k/s1600/Cabozantinib_malate.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="181" src="http://4.bp.blogspot.com/-VB-kSp2B1mU/ULnH7nmx8-I/AAAAAAAAALY/lUkoRRKKM2k/s320/Cabozantinib_malate.png" width="320" /></a></div>
<br />
Cabozantinib (research codes: XL-184, BMS-907351; IUPAC:&nbsp;<span style="font-family: TimesNewRomanPSMT; font-size: 12pt;">Cabozantinib (</span><span style="font-family: TimesNewRomanPS; font-size: 12pt; font-style: italic;">S</span><span style="font-family: TimesNewRomanPSMT; font-size: 12pt;">)-malate is described
chemically as </span><span style="font-family: TimesNewRomanPS; font-size: 12pt; font-style: italic;">N</span><span style="font-family: TimesNewRomanPSMT; font-size: 12pt;">-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-</span><span style="font-family: TimesNewRomanPS; font-size: 12pt; font-style: italic;">Nâ€™</span><span style="font-family: TimesNewRomanPSMT; font-size: 12pt;">-(4-fluorophenyl)cyclopropane-
1,1-dicarboxamide, Standard InChI:&nbsp;</span>ONIQOQHATWINJY-UHFFFAOYSA-N) is dosed as the (S)-malate salt. The parent molecule, cabozantinib, has a molecular weight of 501.5 and a ACD/LogP of 3.08. The effective half-life is ~55 hours, the oral volume of distribution (V/F) is ~349 L, and the clearance (CL/F) at steady-state is estimated to be 4.4 L/hr.<br />
<br />
Cabozantinib has been given a boxed warning due to sever, sometimes fatal haemorrhaging in 3% of patients and gastrointestinal perforations in 3% and fistula formation in 1% of treated patients. <br />
<br />
Cabozantinib is a multi-kinase inhibitor, and inhibits the following tyrosine kinases in vitro: RET (<a href="http://www.uniprot.org/uniprot/P07949">P07949</a>), MET (<a href="http://www.uniprot.org/uniprot/P08581">P08581</a>), FLT1 (aka VEGFR1, <a href="http://www.uniprot.org/uniprot/P17948">P17948</a>), KDR (aka VEGFR2, <a href="http://www.uniprot.org/uniprot/P35968">P35968</a>), FLT4 (aka VEGFR3, <a href="http://www.uniprot.org/uniprot/P35916">P35916</a>), KIT (<a href="http://www.uniprot.org/uniprot/P10721">P10721</a>), NTRK2 (TRKB <a href="http://www.uniprot.org/uniprot/Q16620">Q16620</a>), FLT3 (<a href="http://www.uniprot.org/uniprot/P36888">P36888</a>), AXL (<a href="http://www.uniprot.org/uniprot/P30530">P30530</a>), and TEK (aka TIE2, <a href="http://www.uniprot.org/uniprot/Q02763">Q02763</a>).<br />
<br />
Prescribing information can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf">here</a>.<br />
<br />
The license holder for Cometriq<sup>TM</sup> is <a href="http://www.exelixis.com/">Exelexis Inc</a> and the product website can be found <a href="http://www.cometriq.com/">here</a>